Exogenous hormone use and fibrocystic breast disease by histopathologic component
- 1 October 1984
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 34 (4) , 443-449
- https://doi.org/10.1002/ijc.2910340403
Abstract
In a hospital‐based case‐control study of 590 women with biopsy‐proven fibrocystic breast disease and 1,018 control women with other surgical conditions, no linear relationship was evident between the use of oral contraceptives or of estrogen replacement therapy and the degree of epithelial atypia of the fibrocystic lesions. Case‐control and intracase comparisons suggested that oral contraceptive use might be associated with an increased occurrence of sclerosing adenosis among the premenopausal women and of gross cysts among the postmenopausal women. Estrogen replacement therapy, which was positively associated with fibrocystic breast disease as a whole among the postmenopausal women, was most frequently used among the cases whose biopsy specimens exhibited gross cysts, papillomatosis or papillary hyperplasia.Keywords
This publication has 35 references indexed in Scilit:
- BREAST CANCER IN YOUNG WOMEN AND USE OF ORAL CONTRACEPTIVES: POSSIBLE MODIFYING EFFECT OF FORMULATION AND AGE AT USEThe Lancet, 1983
- Fibrocystic Disease of the Breast — A Nondisease?New England Journal of Medicine, 1982
- Contraceptive Technology 1982-1983Studies in Family Planning, 1982
- Breast cancer and oral contraceptives: findings in Royal College of General Practitioners' study.BMJ, 1981
- An epidemiological study of oral contraceptives and breast cancerBMJ, 1979
- An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen usePublished by Elsevier ,1979
- Fibrocystic Breast Disease in Oral-Contraceptive UsersNew England Journal of Medicine, 1978
- The Relationship of Gross Cystic Disease of the Breast and CarcinomaAnnals of Surgery, 1977
- Oral Contraceptives and Breast Neoplasia: A Retrospective StudyBMJ, 1972